CCO Treatment Updates
Assessing Antiretroviral Activity: A Practical Guide to Selecting New Agents for Treatment-Experienced Patients
Interactive Virtual Presentation
Assessing Antiretroviral Activity: A Practical Guide to Selecting New Agents for Treatment-Experienced Patients
|
|
|
Watch, listen, and make treatment decisions as Charles B. Hicks, MD, leads you through this interactive presentation exploring the application of various tools and approaches, including resistance and tropism tests, to assess the activity of antiretroviral agents to individualize treatment for antiretroviral-experienced patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of resistance testing in assessing the potential activity of an antiretroviral regimen
- Summarize clinical data pertaining to the impact of NRTI and NNRTI resistance on the efficacy of subsequent lines of therapy with agents from these classes
- Define what is meant by a high genetic barrier to resistance and cite clinical examples as they relate to PI treatment
- Discuss the role of agents from new classes in contributing to the number of active agents in an antiretroviral regimen
- Summarize clinical evidence regarding the ideal number of active agents that should be included in a new antiretroviral regimen for treatment-experienced patients
|
Slideset: Assessing Antiretroviral Activity: A Practical Guide to Selecting New Agents for Treatment-Experienced Patients
 |
|
Charles B. Hicks, MD, discusses the latest findings from clinical studies regarding the impact of HIV resistance and tropism on the assessment of the antiretroviral activity of specific agents in designing new regimens for treatment-experienced patients.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.83 MB
| Date posted: 11/24/2008
|
Case Vignettes
Treatment Options for a Patient With Persistent Viremia on Enfuvirtide-Containing Therapy |
Module 1 of 3 |
|
|
|
Joseph J. Eron, Jr., MD, discusses assessment of treatment options for a patient with multidrug resistance failing an enfuvirtide-containing regimen.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the significance of the number of fully active agents in new regimens for antiretroviral-experienced patients
- Discuss the significance of archived NNRTI mutations in assessing the activity of etravirine
- Describe the role of clinical cut-offs in designing regimens for antiretroviral-experienced patients
|
Designing a New Regimen for a Highly Treatment–Experienced Patient With R5-Only Virus |
Module 2 of 3 |
|
|
|
Richard Haubrich, MD, explores key issues to be considered in incorporating novel agents into a new treatment regimen for a patient with extensive antiretroviral experience.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify key concerns regarding drug-drug interactions in designing antiretroviral regimens
- Describe the significance of enfuvirtide susceptibility in designing regimens for antiretroviral-experienced patients
- Describe considerations in the use of newer PIs and NNRTIs that have activity against drug-resistant HIV for treatment-experienced patients
- Discuss issues in selecting how many agents and which classes to include in regimens for highly treatment–experienced patients
|
Selecting and Modifying First-line Antiretroviral Therapy in a Pregnant Patient With Transmitted Drug Resistance |
Module 3 of 3 |
|
|
|
Charles B. Hicks, MD, discusses potential strategies for choosing an initial antiretroviral regimen for a pregnant woman with transmitted resistance.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the significance of transmitted antiretroviral resistance on choice of an initial HAART regimen
- Define the limitations of the currently available standard genotyping techniques for HIV-infected patients
- Identify antiretroviral classes approved for use in treatment-naive patients that have a high genetic barrier to resistance
- Discuss the importance of assessing the antiviral activity of each of the components of a regimen prior to modification
Abstract
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|